Antigen presentation by parenchymal cells: A route to peripheral tolerance?

Immunological Reviews

Volumn 172, Issue , 1999, Pages 297-314

  Marelli Berg, Federica M ^a   Lechler, Robert I ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CLONAL ANERGY; ENDOTHELIUM CELL; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; MOUSE; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION;

EID: 0033407382     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065x.1999.tb01374.x     Document Type: Article

References (166)

1. 1. Bretscher P, Cohn M. A theory of self-nonself discrimination. Paralysis and induction involve the recognition of one and two determinants on an antigen, respectively. Science 1970;169:1042-1049.
2. 2. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
3. 3. Medzhitov R, Janeway CA Jr. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997;9:4-9.
4. 4. June CH, Ledbetter JA, Gillespie MM, Lindsten T, Thompson CB. T cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol 1987;7:4772-4778.
5. 5. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991;147:2461-2466.
6. 6. Azuma M, Cayabab M, Buck D, Phillips JH, Lanier LL. CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J Exp Med 1992;175:353-360.
7. 7. Damle NK, Doyle LV, Grosmaire LS, Ledbetter JA. Differential regulatory signals delivered by the antibody binding to the CD28 (Tp44) molecule during the activation of human T lymphocytes. J Immunol 1988;140:1753-1761.
8. 8. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T cell clones. Nature 1992;356:607-609.
9. 9. Shainian A, et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993;261:609-612.
10. 10. Green JM, et al. Absence of B7-dependent responses in CD28-deficient mice. Immunity 1994;1:501-508.
11. 11. Sperling AI, Auger JA, Ehst BD, Rulifson IC, Thompson CB, Bluestone JA. CD28/B7 interaction deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. J Immunol 1996;157:3909-3917.
12. 12. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA 1990;87:5031-5035.
13. 13. Freeman GJ, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates T cell activation. Science 1993;262:909-911.
14. 14. Azuma M, et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993;366:76-79.
15. 15. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4. Immunity 1994;1:793-801.
16. 16. Brunet JF, et al. A new member of the immunoglobulin superfamily - CTLA-4. Nature 1987;328:267-270.
17. 17. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B-cell activation antigen B7. J Exp Med 1991;174:561-569.
18. 18. Lindsten T, et al. Characterization of CTLA-4 structure and expression on human T cells. J Immunol 1993;151:3489-3499.
19. 19. Damle NK, Klussman K, Leytze G, Myrdal S, Aruffo A, Ledbetter JA. Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7. J Immunol 1994;152:2686-2697.
20. 20. Walunas TL, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-413.
21. + T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J Immunol 1995;155:1032-1036.
22. 22. Tivol EA, Bordello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-547.
23. 23. Bluestone JA. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 1995;2:555-559.
24. 24. Lassila O, Vanio O, Matzinger P. Can B cells turn on virgin T cells? Nature 1988;334:253-255.
25. 25. Windhagen A, et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86) and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995;182:1985-1996.
26. 26. Verwilghen J, et al. Expression of functional B7 and CTLA4 on rheumatoid synovial T cells. J Immunol 1994;153:1378-1385.
27. 27. Tandon M, Metcalfe R, Barnett D, Weetman A. Expression of the costimulatory molecule B7/BB1 antigen in autoimmune thyroid disease. Q J Med 1994;87:231-236.
28. 28. Simon J, et al. Expression of the B7/BB1 antigen and its ligand CD28 in T-cell-mediated skin diseases. J Invest Dermatol 1994;103:539-543.
29. 29. Nickoloff B, Nestle F, Zheng X, Turka L. T lymphocytes in skin lesion of psoriasis and mycosis fungoides express B71: a ligand for CD28. Blood 1994;83:2580-2586.
30. 30. Bottazzo GF, Pujol-Borrell R, Hanafusa T, Feldmann M. Role of aberrant HLA-DR expression and antigen expression in induction of endocrine autoimmunity. Lancet 1983;ii:1115-1119.
31. 31. Visscher D, et al. Histologic and immunophenotypic evaluation of pretreatment renal biopsies on OKT3-treated allograft rejections. Transplantation 1991;51:1023-1028.
32. 32. Asakawa H, Hanafusa T, Kuma K, Kono N, Tarui S. Function of DR-positive thyrocytes from patients with Graves' disease: quantitative analysis of thyroid peroxidase content by fluorescent photometry. J Clin Endocrinol Metab 1992;74:614-618.
33. 33. Hytiroglou P, et al. FK506 versus cyclosporine as primary immunosuppresive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. Transplantation 1993;56:1386-1394.
34. 34. Coleman N, Stanley MA. Analysis of HLA-DR expression on keratinocytes in cervical neoplasia. Int J Cancer 1994;56:314-319
35. 35. Brookes SM, Price EJ, Venables PJ, Maini RN. Interferon-γ and epithelial cell activation in Sjögren's syndrome. Br J Rheumatol 1995;34:226-231.
36. 36. Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. Decreased dependence of myelin basic protein reactive T cells on CD28 mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J Clin Invest 1998;101:725-730.
37. 37. Tan P, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993;177:165-173.
38. 38. Boussiotis VA, Freeman GJ, Gray G, Gribben J, Nadler LM. B7 but not intercellular adhesion molecule-1 prevents the induction of human alloantigen-specific tolerance. J Exp Med 1993;178:1753-1763.
39. + T cells. J Immunol 1997;159:5853-5861.
40. 40. Frasca L, et al. Interferon-γ-treated renal tubular epithelial cells induce allospecific tolerance. Kidney Int 1997;53:679-689.
41. 41. Londei M, Lamb JR, Bottazzo GF, Feldmann M. Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature 1984;312:639-641.
42. 42. Londei M, Bottazzo GF, Feldmann M. Human T cell clones from autoimmune thyroid glands: specific recognition of autologous thyroid cells. Science 1985;228:85-89.
43. 43. Weetman AP, et al. The production and characteristics of thyroid-derived T cell lines in Graves' disease and Hashimoto's thyroiditis. Clinical Immunol Immunopathol 1986;39:131-150.
44. 44. Dayan CM, et al. Autoantigen recognition by thyroid-infiltrating T cells in Graves' disease. Proc Natl Acad Sci USA 1991;88:7415-7419.
45. 45. Nickoloff BJ, et al. Accessory cell function of keratinocytes for superantigens. Dependence on lymphocyte function associated antigen 1/intercellular adhesion molecule 1 interaction. J Immunol 1993;150:2148-2159.
46. 46. Nickoloff BJ, et al. Discordant expression of CD28 ligands, BB 1, and B7 on keratinocytes in vitro and psoriatic cells in vivo. Am J Pathol 1993;142:1029-1040.
47. 47. Gaspari AA, Jenkins MK, Katz SI. Class II MHC-bearing keratinocytes induce antigen-specific unresponsiveness in hapten-specific Th1 clones. J Immunol 1988;141:2216-2220.
48. 48. Bal V, et al. Antigen presentation by keratinocytes induces tolerance in human T cells. Eur J Immunol 1990;20:1893-1897.
49. 49. Markman J, Lo D, Naji A, Palmiter RD, Brinster RL, Herber-Katz E. Antigen-presenting cell function of class II MHC-expressing pancreatic β cells. Nature 1988;336:476-479.
50. 50. Lombardi G,et al. Antigen presentation by interferon-γ-treated thyroid follicular cells inhibits interleukin-2 (IL-2) and supports IL-4 production by B7-dependent human T cells. Eur J Immunol 1997;27:62-71.
51. + T cells by delivery of the B7 costimulatory signal on bystander antigen-presenting cells (trans-costimulation). Eur J Immunol 1994;24:859-866.
52. 52. Liu Y, Janeway CA Jr. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc Natl Acad Sci USA 1992;89:3845-3849.
53. 53. Galvin F, et al. Murine B7 antigen provides a sufficient costimulatory signal for antigen-specific and MHC-restricted T cell activation. J Immunol 1992;149:3802-3808.
54. 54. Marelli-Berg FM, Barroso-Herrera O, Lechler RI. Recently activated T cells are costimulation-dependent in vitro. Cell Immunol (In press).
55. 55. Shahinian A, et al. Differential T cell costimulatory requirements in CD28 deficient mice. Science 1993;261:609-612
56. 56. Kundig TM, et al. Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity 1996;5:41-52.
57. 57. Champagne E, Scarpellino L, Lane P, Acha Orbea H. CD28/CTLA4 B7 interaction is dispensable for T cell stimulation by mouse mammary tumor virus superantigen but not for B cell differentiation and virus dissemination. Eur J Immunol 1996;26:1595-1602.
58. 58. Corry DB, Reiner SL, Linsley PS, Locksley RM. Differential effects of blockade of CD28 B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. J Immunol 1994;153:4142-4148.
59. 59. Brown DR, Green JM, Moskowitz NH, Davis M, Thompson CB, Reiner SL. Limited role of CD28 mediated signals in T helper subset differentiation. J Exp Med 1996;184:803-810.
60. 60. Bachmann MF, Zinkernagel RM, Oxenius A. Immune responses in the absence of costimulation: viruses know the trick. J Immunol 1998;161:5791-5794.
61. 61. Lanzavecchia A. How can cryptic epitopes trigger autoimmunity? J Exp Med 1995;181:1945-1948.
62. 62. Quaratino S, Feldmann M, Dayan CM, Acuto O, Londei M. Human self-reactive T cell clones expressing identical T cell receptor β chains differ in their ability to recognize a cryptic self-epitope. J Exp Med 1996;183:349-358.
63. 63. Bohme J, et al. Transgenic mice with I A on islet cells are normoglycemic but immunologically intolerant. Science 1989;244:1179-1183.
64. 64. Miller J, Daitch L, Rath S, Seising E. Tissue specific expression of allogeneic class II MHC molecules induces neither tissue rejection nor clonal inactivation of alloreactive T cells. J Immunol 1990;144:334-341.
65. 65. Burkly LC, Lo D, Kanagawa O, Brinster RL, Flavell R. T cell tolerance by clonal anergy in transgenic mice with nonlymphoid expression of MHC class II I-E. Nature 1989;342:564-566.
66. 66. Lo D, Burkly LC, Flavell RA, Palmiter RD, Brinster RL. Tolerance in transgenic mice expressing class II major histocompatibility complex on pancreatic acinar cells. J Exp Med 1989;170:87-104.
67. 67. Lo D, et al. Diabetes and tolerance in transgenic mice expressing class II MHC molecules in pancreatic β cells. Cell 1988;53:159-168.
68. b in the liver. Eur J Immunol 1995;25:1932-1942.
69. 69. Schönrich G, et al. Downregulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell 1991;65:293-304.
70. 70. Ohashi PL, et al. Ablation of 'tolerance' and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991;65:305-331.
71. 71. Morahan G, Allison J, Miller JF. Tolerance of class I histocompatibility antigens expressed extrathymically. Nature 1989;339:622-624.
72. 72. Arnold B, Schönrich G. Hämmerling GJ. Multiple levels of peripheral tolerance. Immunol Today 1993;14:12-14.
73. 73. Ferber I, Schönrich G, Schenkel J, Mellor AL, Hämmerling GJ, Arnold B. Levels of T cell tolerance induced by different doses of tolerogen. Science 1994;263:674-676.
74. 74. Heath WR, et al. Autoimmune diabetes as a consequence of locally produced interleukin 2. Nature 1992;359:547-549.
75. + T cells is transient and depends on avidity. J Immunol 1995;155:2339-2349.
76. 76. Limmer A, et al. Failure to induce organ specific autoimmunity by breaking of tolerance: importance of the microenvironment. Eur J Immunol 1998;28:2395-2406.
77. 77. Alferink J, Tafuri A, Vestweber D, Hallmann R, Hämmerling GJ, Arnold B. Control of neonatal tolerance to tissue antigens by peripheral T cell trafficking. Science 1998;282:1338-1341.
78. 78. Kurts C, Heath WR, Carbone F, Allison J, Miller JFAP, Kosaka H. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med 1996;184:923-930.
79. + T cells. J Exp Med 1997;186:239-245.
80. 80. Wood ML, Monaco AP. Induction of unresponsiveness to skin allografts in adult mice disparate at defined regions of the H 2 complex. Effect of pre-graft donor specific blood transfusions in ALS treated mice. Transplantation 1984;37:39-42.
81. 81. Talmage DW, La Rosa FG, Smilek D, Ammons TJ. The tolerance that develops in recipients of cultured allografts is an active process that affects both the activation and effector function of cytotoxic T cells. Prog Clin Biol Res 1986;224:187-194.
82. 82. La Rosa FG, Talmage DW. Tolerance to cultured allografts protects third party grafts containing new MHC and common minor antigens. Transplantation 1987;43:314-316.
83. 83. Herbert J, Roser B. Strategies of monoclonal antibody therapy that induce permanent tolerance of organ transplants. Transplantation 1988;46:128S-134S.
84. 84. Wheelahan J, McKenzie IF. Tolerance induction to murine class II MHC molecules by anti CD4 antibody. Transplant Proc 1989;21:246-247.
85. 85. Sayegh MH, Km JP, Milford EL. Anti-CD4 monoclonal antibody effects cellular hyporesponsiveness and prolongs renal allograft survival in the rat. Hum Immunol 1989;26:131-136.
86. + suppressor cell and its mechanisms of action. J Exp Med 1990;171:141-157.
87. 87. Ruiz P, Fuller J, Sanfilippo F. Donor specific cellular immunity in rejecting and long term surviving class I disparate rat renal allograft recipients. Transplantation 1990;49:175-183.
88. 88. Mason PD, Robinson CM, Lechler RI. Detection of donor-specific hyporesponsiveness following late failure of human renal allograft. Kidney Int 1996;50:1019-1025.
89. 89. Hornick PI, Mason PD, Yacoub MH, Rose ML, Batchelor R, Lechler RI. Assessment of the contribution that direct recognition makes to the progression of chronic cardiac transplant rejection in humans. Circulation 1998;97:1257-1263.
90. 90. Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975;53:27-42.
91. 91. Lafferty KJ, Cooley MA, Woolnough J, Walker KZ. Thyroid allograft immunogenicity is reduced after a period in organ culture. Science 1975;188:259-261.
92. 92. Lafferty KJ, Bootes A, Dart G, Talmage DW. Effect of organ culture on the survival of thyroid allografts in mice. Transplantation 1976;22:138-149.
93. 93. Lacy PE, Davie JM, Finke EH. Prolongation of islet xenograft survival without continuous immunosuppression. Science 1979;209:283-285.
94. 94. Talmage DW, Dart G, Radovich J, Lafferty KJ. Activation of transplant immunity: effect of donor leukocytes on thyroid allograft rejection. Science 1976;191:385-388.
95. 95. Batchelor JR, Welsh KI, Maynard A, Burgos H. Failure of long surviving, passively enhanced kidney allografts to provoke T-dependent alloimmunity. Retransplantation of (AS X AUG)F1 kidneys into secondary AS recipients. J Exp Med 1979;150:455-464.
96. 96. Welsh KI, Batchelor JR, Maynard A, Burgos H. Failure of long surviving, passively enhanced kidney allografts to provoke T-dependent alloimmunity II. Retransplantation of (AS X AUG)F1 kidneys from AS primary recipients into (AS X WF)F1 secondary hosts. J Exp Med 1979;150:465-470.
97. 97. Lechler RI, Batchelor JR. Immunogenicity of retransplanted rat kidney allografts. Effect of inducing chimerism in the first recipient and quantitative studies on immunosuppression of the second recipient. J Exp Med 1982;156:1835-1841.
98. 98. Lechler RI, Batchelor JR. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982;155:31-41.
99. 99. Braun MY, McCormack A, Webb G, Batchelor JR. Evidence for clonal anergy as a mechanism responsible for the maintenance of transplantation tolerance. Eur J Immunol 1993;23:1462-1468.
100. 100. Armstrong HE, Bolton EM, McMillan I, Spencer SC, Bradley JA. Prolonged survival of actively enhanced rat renal allografts despite accelerated cellular infiltration and rapid induction of both class I and class II MHC antigens. J Exp Med 1987;165:891-907.
101. 101. Dallman MJ, Wood KJ, Morris PJ. Specific cytotoxic T cells are found in the nonrejected kidneys of blood-transfused rats. J Exp Med 1987;165:566-571.
102. 102. Dallman MJ, Shimo O, Page TH, Wood KJ, Morris PJ. Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med 1991;173:79-87.
103. 103. Lenschow DJ, et al. Long term survival of xenogeneic pancreatic islet grafts induced by CTLA-4Ig. Science 1992;257:789-792.
104. 104. Lin H, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993;178:1801-1806.
105. 105. Baliga P, et al. CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation 1994;58:1082-1090.
106. 106. Sayegh MH, et al. CD28 B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995;181:1869-1874.
107. 107. Coulombe M, Gill RG. Tolerance induction to cultured islet allografts. I: Characterization of the tolerant state. Transplantation 1994;57:1195-1200.
108. 108. Coulombe M, Gill RG. Tolerance induction to cultured islet allografts. II: The status of antidonor reactivity in tolerant animals. Transplantation 1994;57:1201-1207.
109. 109. Coulombe M, Lafferty KJ, Gill RG. Nature of tolerance induction to peripheral (extrathymic) islet allografts. Transplant Proc 1994;26:720-721.
110. 110. Coulombe M, Gill RG. T lymphocyte indifference to extrathymic islet allografts. J Immunol 1996;156:1998-2003.
111. 111. Coulombe M, Yang H, Gill RG. Adoptive transfer of CD4 T cell dependent allograft tolerance. Transplant Proc 1997;29:1166-1167.
112. 112. Coulombe M, Yang H, Wolf LA, Gill RG. Tolerance to antigen-presenting cell-depleted islet allografts is CD4 T cell dependent. J Immunol 1999;162:2503-2510.
113. 113. Konieczny BT, et al. IFN-γ is critical for long term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J Immunol 1998;160:2059-2064.
114. 114. Larsen CP, et al. Long term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381:434-438.
115. 115. Kearney ER, Pape KA, Loh DY, Jenkins MK. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1994;1:327-339.
116. 116. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell Tolerance in vivo requires CTLA-4 engagement. Immunity 1997;6:411-417.
117. 117. Linsley PS, et al. Coexpression and functional cooperation of CTLA 4 and CD28 on activated T lymphocytes. J Exp Med 1992;176:1595-1604.
118. 118. Alegre ML, et al. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol 1996;157:4762-4770.
119. 119. Judge TA, Wu Z, Zheng X-G, Sharpe AH, Sayegh MH, Turka LA. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol 1999;162:1947-1951.
120. 120. Rose MR, Coles MI, Griffin RJ, Pomerance A, Yacoub MH. Expression of class I and class II major histocompatibility antigens in normal and transplanted human heart. Transplantation 1986;41:776-781.
121. 121. Fuggle SV, McWhinnie DL, Chapman JR, Taylor HM, Morris PJ. Sequential analysis of HLA-class II antigen expression in human renal allografts. Transplantation 1986;41:144-149.
122. 122. Steinhoff G, Wonigeit K, Pichlma R. Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. Transplantation 1988;45:394-398.
123. 123. Hughes CCW, Savage COS, Pober JS. Endothelial cells augment T cell interleukin 2 production by a contact-dependent mechanism involving CD2/LFA-3 interaction. J Exp Med 1990;171:1453-1467.
124. 124. Wagner CR, Vetto RM, Burger DR. Subcultured endothelial cells can function independently as fully competent antigen-presenting cells. Hum Immunol 1985;13:33-47.
125. 125. Geppert TD, Lipsky PE. Antigen presentation by interferon-γ-treated endothelial cells and fibroblasts: differential ability to funnction as antigen-presenting cells despite comparable Ia expression. J Immunol 1985;135:3750-3762.
126. + allogeneic vascular endothelium. Identification of accessory interactions. Transplatation 1993;56:128-134.
127. 127. Page C, Holloway N, Smith H, Yacoub M, Rose M. Alloproliferative responses of purified resting CD4 and CD8 T cells to endothelial cells in the absence of contaminating accessory cells. Transplantation 1994;57:1628-1637.
128. + T-cell responses to human allogeneic microvascular endothelium. Circ Res 1991;69:1769-1279.
129. + lymphocytes. Transplantation 1993;56:656-661.
130. 130. Marelli-Berg FM, Hargreaves REG, Carmichael P, Dorling A, Lombardi G, Lechler RI. Major Histocompatibility Complex Class II-expressing endothelial cells induce allospecific nonresponsiveness in naive T cells. J Exp Med 1996;183:1603-1612.
131. 131. Nunez G, Ball EJ, Stastny P. Accessory cell function of human endothelial cells. I. A subpopulation of Ia positive cells is required for antigen presentation. J Immunol 1983;131:666-671.
132. 132. Mackay CR. Homing of naive, memory and effector lymphocytes. Curr Opin Immunol 1993,5:423-427.
133. 133. StLouis JD, Lederer JA, Lichtman AH. Costimulator deficient antigen presentation by an endothelial cell line induces a nonproliferative T cell activation response without anergy. J Exp Med 1993;178:1597-1605.
134. 134. Savage CO, et al. Human vascular endothelial cells process and present autoantigen to human T cell lines. Int Immunol 1995;7:471-479.
135. 135. Marelli-Berg FM, Frasca L, Lombardi G, Lechler RI. Lack of T cell proliferation without induction of nonresponsiveness following antigen presentation by endothelial cells. Transplantation (In press).
136. + T lymphocytes. J Immunol 1992;148:1985-1992.
137. + T cells. J Immunol 1998;161:2158-2167.
138. 138. Sancho D, Yanez-Mo M, Tejedor R, Sanchez-Madrid F. Activation of peripheral blood T cells by interaction and migration through endothelium: role of lymphocyte function antigen-1/intercellular adhesion molecule-1 and interleukin-15. Blood 1999;93:886-896.
139. 139. Offner H, et al. Where, when, and how to detect biased expression of disease relevant V β genes in rats with experimental autoimmune encephalomyelitis. J Immunol 1993;151:506-517.
140. 140. Karin N, Szafer F, Mitchell D, Gold DP, Steinman L. Selective and nonselective stages in homing of T lymphocytes to the central nervous system during experimental allergic encephalomyelitis. J Immunol 1993;150:4116-4124.
141. 141. Kawai T, Shimauchi H, Eastcott JW, Smith DJ, Taubman MA. Antigen direction of specific T-cell clones into gingival tissues. Immunology 1998;93:11-19.
142. 142. Dustin ML, Bromley SK, Kan Z, Peterson DA, Unanue ER. Antigen receptor engagement delivers a stop signal to migrating T lymphocytes. Proc Natl Acad Sci USA 1997;94:3909-3913.
143. 143. Ben Nun A, et al. Restricted T cell receptor V β gene usage by myelin basic protein specific T cell clones in multiple sclerosis: predominant genes vary in individuals. Proc Natl Acad Sci USA 1991;88:2466-2470.
144. 144. Kotzin BL, et al. Preferential T cell receptor β-chain variable gene use in myelin basic protein reactive T cell clones from patients with multiple sclerosis. Proc Natl Acad Sci USA 1991;88:9161-9165.
145. 145. Howell MD, et al. Limited T cell receptor β chain heterogeneity among interleukin 2 receptor positive synovial T cells suggests a role for superantigen in rheumatoid arthritis. Proc Natl Acad Sci USA 1991;88:10921-10925.
146. 146. Sottini A, Imberti L, Gorla R, Cattaneo R, Primi D. Restricted expression of T cell receptor Vβ but not Vα genes in rheumatoid arthritis. Eur J Immunol 1991;21:461-466.
147. 147. Davies TF, Martin A, Concepcion ES, Graves P, Cohen L, Ben Nun A. Evidence of limited variability of antigen receptors on intrathyroidal T cells in autoimmune thyroid disease. N Engl J Med 1991;325:238-244.
148. 148. Moller DR, Konishi K, Kirby M, Balbi B, Crystal RG. Bias toward use of a specific T cell receptor β-chain variable region in a subgroup of individuals with sarcoidosis. J Clin Invest 1988;82:1183-1191.
149. 149. Miltenburg AM, van Laar JM, Daha MR, de Vries RR, van den Elsen PJ, Breedveld FC. Dominant T cell receptor β chain gene rearrangements indicate clonal expansion in the rheumatoid joint. Scand J Immunol 1990;31:121-126.
150. 150. Wucherpfennig KW, et al. Shared human T cell receptor Vβ usage to immunodominant regions of myelin basic protein. Science 1990;248:1016-1019.
151. 151. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992;35:729-735.
152. + T cells that exhibit a transendothelial migratory capacity. J Immunol 1995;154:3062-3077.
153. 153. Dustin ML, Springer TA. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-I. Nature 1989;341:619-624.
154. 154. Van Kooyk Y, van de Wiel-van Kemenade P, Weder P, Kuijpers TW, Figdor CG. Enhancement of LFA-I-mediated cell adhesion by triggering through CD2 or CD3 on T lymphocytes. Nature 1989;342:811-813.
155. 155. Dransfield I, Cabanas C, Barrett J, Hogg N. Interaction of leukocyte integrins with ligand is necessary but not sufficient for function. J Cell Biol 1992;116:1527-1535.
156. 156. Lin J, et al. CD3 and CD2 ligation alters CD49d epitope expression. Pathobiology 1995;63:119-132.
157. + T cells. J Immunol 1999;162:696-703.
158. 158. Reul RM, et al. CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection. Transplantation 1997;64:1765-1774.
159. 159. Hollenbaugh D, et al. Expression of functional CD40 by vascular endothelial cells. J Exp Med 1995;182:33-40.
160. 160. Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 1995;92:4342-4346.
161. + T cells through a CD2/LFA-3 signaling pathway. Eur J Immunol 1996;26:610-617.
162. 162. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo AA. 39 kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci USA 1992;89:6550-6554.
163. 163. Niimi M, et al. The role of the CD40 pathway in alloantigen induced hyporesponsiveness in vivo. J Immunol 1998;161:5331-5337.
164. + T cells. Science 1996;271:1276-1278.
165. 165. Lombardi G, Sidhu S, Batchelor R, Lechler RI. Anergic T cells as suppressor cells in vitro. Science 1994;264:1587-1589.
166. 166. Frasca L, Carmichael P, Lechler R, Lombardi G. Anergic T cells effect linked suppression. Eur J Immunol 1997;27:3191-3197.